Mechanistic Studies of a T20-Dependent Human Immunodeficiency Virus Type 1 Variant
- 1 August 2008
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 82 (15), 7735-7740
- https://doi.org/10.1128/jvi.02524-07
Abstract
We previously described a T20-dependent human immunodeficiency virus type 1 variant from a patient on T20 therapy (3). This virus carries two mutations in the gp41 domain of the envelope protein (Env) that was proposed to undergo a premature conformational switch to the 6-helix bundle structure. The T20 peptide can rescue this hyperfusogenic Env protein by preventing the premature switch and preserving an earlier prefusion conformation, thus restoring virus infectivity and replication. In this study, we set out to critically test this mechanistic explanation with alternative effectors that may control the Env switch, including other fusion inhibitors and antibodies that target gp41.Keywords
This publication has 25 references indexed in Scilit:
- Selection of T1249-Resistant Human Immunodeficiency Virus Type 1 VariantsJournal of Virology, 2008
- A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodiesProceedings of the National Academy of Sciences, 2008
- HIV-1 drug-resistance and drug-dependenceRetrovirology, 2007
- Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1Journal of Medical Virology, 2005
- Emergence and Evolution of Enfuvirtide Resistance following Long-Term Therapy Involves Heptad Repeat 2 Mutations within gp41Antimicrobial Agents and Chemotherapy, 2005
- Emergence of a Drug-Dependent Human Immunodeficiency Virus Type 1 Variant during Therapy with the T20 Fusion InhibitorJournal of Virology, 2004
- The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected AdultsAIDS Research and Human Retroviruses, 2002
- Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) MonotherapyAntimicrobial Agents and Chemotherapy, 2002
- Protein Design of an HIV-1 Entry InhibitorScience, 2001
- Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.Proceedings of the National Academy of Sciences, 1994